Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Continuous improvement versus innovation: the case for sipuleucel-T.

Tombal B.

Eur Urol. 2012 Apr;61(4):648-9; discussion 650-1. doi: 10.1016/j.eururo.2011.11.033. No abstract available.

PMID:
22154024
2.

The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.

Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.

Eur Urol. 2012 Apr;61(4):639-47. doi: 10.1016/j.eururo.2011.10.027. Review.

PMID:
22036643
3.

How does sipuleucel-T alter our clinical practice?

George D.

BJU Int. 2010 Oct;106(7):945-6. No abstract available.

PMID:
20931691
4.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Sartor O.

BJU Int. 2012 Jul;110(2 Pt 2):E105. doi: 10.1111/j.1464-410X.2011.10820.x. No abstract available.

5.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Tanimoto T, Hori A, Kami M.

N Engl J Med. 2010 Nov 11;363(20):1966; author reply 1967-8. doi: 10.1056/NEJMc1009982#SA1. No abstract available.

PMID:
21067392
6.

Sipuleucel-T for the treatment of advanced prostate cancer.

Frohlich MW.

Semin Oncol. 2012 Jun;39(3):245-52. doi: 10.1053/j.seminoncol.2012.02.004. Review.

PMID:
22595047
7.

Sipuleucel-T in metastatic castration-resistant prostate cancer: profile report.

Plosker GL.

BioDrugs. 2011 Aug 1;25(4):255-6. doi: 10.2165/11207140-000000000-00000. No abstract available.

PMID:
21815700
8.

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

Drake CG.

J Natl Cancer Inst. 2012 Sep 19;104(18):1422; author reply 1422-3. No abstract available.

PMID:
22911668
9.

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF.

J Natl Cancer Inst. 2012 Jul 18;104(14):1107-9; author reply 1109-12. doi: 10.1093/jnci/djs279. No abstract available.

PMID:
22825556
10.

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

Gulley JL, Leitman SF, Dahut W, Schlom J.

J Natl Cancer Inst. 2012 Jul 18;104(14):1106; author reply 1109-12. doi: 10.1093/jnci/djs280. No abstract available.

PMID:
22825555
11.

Cabazitaxel in prostate cancer: stretching a string.

Dorff TB, Quinn DI.

Lancet. 2010 Oct 2;376(9747):1119-20. doi: 10.1016/S0140-6736(10)61510-3. No abstract available.

PMID:
20888974
12.

[Sipuleucel-T: a prostate cancer vaccine: "instructions for use" for urologists].

Ouzaid I, Ravery V.

Prog Urol. 2011 Oct;21(9):595-8. doi: 10.1016/j.purol.2011.06.002. French.

PMID:
21943654
13.

Sipuleucel-T (APC8015) for prostate cancer.

So-Rosillo R, Small EJ.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1163-7. Review.

PMID:
17020451
14.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Nabhan C.

N Engl J Med. 2010 Nov 11;363(20):1966-7; author reply 1968. doi: 10.1056/NEJMc1009982#SA2. No abstract available.

PMID:
21067391
15.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators..

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

16.

Sipuleucel-T shows partial advantage in prostate cancer.

Gould P.

Lancet Oncol. 2006 Sep;7(9):710. No abstract available.

PMID:
16981300
17.

Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.

Arlen PM.

Oncology (Williston Park). 2011 Mar;25(3):261-2. Review. No abstract available.

18.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Review.

19.

Lower baseline PSA predicts greater benefit from sipuleucel-T.

Petrylak D.

Clin Adv Hematol Oncol. 2013 Jun;11(6):377-81. No abstract available.

PMID:
24472808
20.

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

Cheever MA, Higano CS.

Clin Cancer Res. 2011 Jun 1;17(11):3520-6. doi: 10.1158/1078-0432.CCR-10-3126.

Items per page

Supplemental Content

Support Center